

Review Article

Production, Characterization and Clinical Applications of Third-generation Cephalosporins

Hira Sundus, Kadija tul kubra, Manam Walait and Sikander Ali*

Institute of Industrial Biotechnology (IIB), GC University Lahore, Pakistan

***Corresponding author**

Sikander Ali

Email: dr.sikanderali@gcu.edu.pk

Abstract: Cephalosporin is one of most widely used drug in world wide. Cephalosporin mechanism of action is more resistant to other agents that have infections from these agents. Its classification ranking 4th generation cephalosporin is more critical than 3rd generation cephalosporin but both are critical in WHO criteria. In human medicines and all risk management factors used cephalosporin antibiotic as one of the major factor. Its production on large scale is very important. Cephalosporin produced from *Cephalosporium acremonium* which immobilized in agar or other agents and cephalosporin antibiotics produced under optimum and favorable conditions. Calcium alginate and glass wool also used for immobilization and repeated batch of shake flask fermentations used for its production. It was recently improved for the treatment of community acquired pneumonia. It has also broad spectrum activity against gram positive and gram negative bacteria. It is also used for the treatment of hospitalized patients. Cephalosporin shows low resistance ratio and safety measurements. It is mostly used for the treatment of skin complicated infections. It will evaluate the pharmacological characters, efficacy, safety, antimicrobial property and its application of cephalosporin in the treatment of community acquired pneumonia.

Keywords: cephalosporin, *Cephalosporium acremonium*, community acquired pneumonia.

INTRODUCTION

Sea water was used first time by Brotzu to isolate *Cephalosporium acremonium* in 1945. Later many scientists worked on it in 1955-56 which was isolated cephalosporin in various forms like C and P and penicillin N also from culture of *acremonium* [1]. Acyl side chain linked with amino group so it resembles with penicillin. Its main disadvantage is low potency of cephalosporin C. Also some semi synthetic derivatives of cephalosporin are also produced like cephalothin and cephaloridine [2]. Modification of cephalosporin gives various compounds having different characteristics. The important broad spectrum antibiotic in international market and is more resistant to penicillin. Mostly cephalosporin C is mostly used for the synthesis of cephalosporins that produced by some other type of fermentation or by aerobic fermentation which are using different strains of *Cephalosporium acremonium* and many other species [3]. The CPC weak antibacterial activity but its modifications and its side chain create various cephalosporins which have diversified effects and antibacterial activity. The mold is renamed as *acremonium chrysogenum*. 65% of penicillin and cephalosporin share worldwide market of antibiotics [4]. Clinical uses of cephalosporins are drugs choice by dental treatment or odontogenic infection or who

persons have allergic responses as alternative of this penicillin used for orodental therapy caused by aerobic bacteria. Adverse reactions of this drug are hypersensitivity reactions, cross reactivity with penicillin, diarrhea, alcohol problem and serious bleeding [5].

The production of cephalosporins in batch as well as continuous culture using free and immobilized cells of mold or any bacterial species reported in various reports having different aspects. The media optimization for production of antibiotic also reported by some authors and different thesis were present [6]. Some reported single constituent of the fermentation of CPC. In media optimization also optimize carbon nitrogen ratio for the synthesis of cephalosporins. By using immobilized cells during production of cephalosporins with various supports like polyacrylamide, calcium alginate and various other compounds. Cephalosporin production by using calcium alginate cells of fungus species. Using special conditions, production of cephalosporin is enhanced by immobilization [7]. Polyacrylamide gel also used for the inactivity of multi enzymes in the mycelium. This gel also entrapped various streptomyces species for

cephalosporin production. Agar immobilization is also used for cephalosporin production [8].

Cephalosporin with penicillin acts as strong antibiotic that inhibit and remove the growth of microorganism. Cephalosporin is more resistant than penicillin against any microbes. The production of cephalosporins in batch as well as continuous culture using free and immobilized cells of mold or any bacterial species reported in various reports having different aspects [9]. The media optimization for production of antibiotic also reported by some authors and different thesis were present. Influence of media constituent in production of cephalosporin and in batch process sucrose is rapidly consuming so such kind of studies very important for the production of antibiotic and good production performance. The present studies deal with the media component that improves the production of cephalosporins [10].




Fig 1: Structure of cephalosporin


Different generations of cephalosporins depend upon different antimicrobial spectrum. Antimicrobial properties are against gram positive decrease but against gram negative increase [11]. Mostly bacteria infections treated by using cephalosporin antibiotic like respiratory tract, infection of skin and infection of urinary tract. Different strains of cephalosporium species are used for the production of cephalosin are used in fermentation which are used as starting material and a process run which requires different factors for good production performance [12]. Submerged and solid state fermentation also used by immobilized cells or organisms. The maximum production of cephalosporin is by using wheat raw and sugar bagasse. As substrate optimization so different other conditions are also important as addition of yeast, soluble starch and pH control and other nutrients [13]. Inoculums level and incubation period also effect the production of cephalosporin by solid state fermentation. Shake flask fermentation best used for production of cephalosporins [14]. In immobilization *Cephalosporium acremonium* spores immobilized in gels and the production of secondary metabolites was higher for immobilized cells than other freely suspended cells. The cephalosporin production by these cells 3-4 times more and chooses entrapment method by immobilization which has good production and investigation of free suspended cells

and confinement in immobilized cells [15]. The structure of cephalosporin is shown in fig 1 [16].

ANTIBIOTIC PRODUCTION FROM MICROBES

Acromonium chrysogenum strain used in fermentation for high yielding to produce such broth has CPC. Purification of fermentation broth is by aqueous solution of CPC. Enzymatic activity is done by purification of such extract to produce aqueous solution of CPC. Precipitation is done of this broth and after this isolation of ACA of appropriate purity 98% for use in the cephalosporin production and intermediate and also active pharmaceutical ingredients [17]. In industrial scale production all ingredients added and it takes three weeks from which two weeks done fermentation and one week for down streaming processing. After down streaming process one day takes for purification, crystallization and drying. After that cephalosporin is crystallized, used and formulated for marketing [18].

Some steps from this outlined production can be changed. Some steps modified or changed such as ion exchange column and crystallization of CPC not require so some procedures will take these steps in already running process [19]. Crystallization of CPC is done in china to make supply easier. CPC are precipitated with zinc salt or any other sodium or potassium salt. Sodium or potassium salts are used for splitting into ACA. Other production methods are also used for the purification and crystallization of product. But cephalosporin also produced synthetically some reactions occur in our body as shown in fig 2 [20].



Biosynthetic Pathway of Cephalosporin C

Fig 2: Biosynthetic pathway of cephalosporin

MECHANISM OF ACTION

Cephalosporin is a fifth generation antibiotic and have similar action as other antibiotics. Cephalosporin binds with penicillin binding proteins and removes the growth of microbes and also prevents the growth of peptidoglycan essential component of

bacterial cell wall. Streptococcus species caused those infections which have affinity for cephalosporins [21]. Cephalosporins bind with penicillin binding proteins which are primary target for bacteria and also resistant strains. The mechanism of action of cephalosporin C is shown in fig 3 [22].




Fig 3: Mechanism of action of antibiotics

MICROBIOLOGICAL ACTIVITY

Gram negative pathogens are treated by broad spectrum cephalosporin. Several studies in vitro activity of cephalosporins have been carried out. A study of such pathogens cephalosporins is to comparator agents [23]. Cephalosporin was found to be eight fold more effective against pneumonia strains than other generation cephalosporins. Cephalosporin show more activity against other pathogens. Another generation cephalosporin group found to be more resistant against 120 types of streptococcus species [24]. Mutations and other penicillin binding proteins have activity against these strains and resistance to beta lactams. In susceptibility study of 891 strains of bacterial species isolated in US which compared those antibiotics with current available cephalosporin antibiotic therapies [25]. Those strains which are resistant to penicillin but cephalosporin are more effective and have more activity against those strains. In some other studies cephalosporins have more activity against 548 strains of *Hemophilus influenza* and 377 strains of some other species, a degree of activity compared with

cephalosporin [26]. In experimental pneumonia model rabbit were inoculated with different strains of bacterial species and in result to eradicate the infection caused by penicillin but some strains are more prior by the treatment of cephalosporins [27].

First generation cephalosporin antibiotic used against methicillin resistance *Staphylococcus aureus*, these characteristics more useful if pathogen continues to increase in frequency. Large series of antibiotics or isolates have bactericidal activity against different bacterial species. The activity of cephalosporins is against different four strains. The bactericidal activity against three strains and reduction in bacterial count is with respect to fourth [28]. Third generation cephalosporin used against gram negative microorganism. Different microbial species have potency against ceftaroline. Hence it is important that ceftaroline has similar function to third generation antibiotics and have not significant effect as beta lactamase producing organism or other microorganisms [29].

Table-1: Spectrum of microbiological coverage

Gram-positive bacteria	References
<i>Staphylococcus aureus</i> (MSSA and MRSA)	[6]
<i>Streptococcus pyogenes</i>	[2]
<i>Streptococcus agalactiae</i>	[14]
<i>Streptococcus pneumoniae</i>	[32]
<i>Streptococcus dysgalactiae</i>	[15]
Gram-negative bacteria	
<i>Klebsiella pneumoniae</i>	[43]
<i>Klebsiella oxytoca</i>	[6]
<i>Escherichia coli</i>	[42]
<i>Citrobacter koseri</i>	[16]
<i>Citrobacter freundii</i>	[9]
<i>Enterobacter cloacae</i>	[18]
<i>Enterobacter aerogenes</i>	[4]
<i>Haemophilus influenza</i>	[10]
<i>Haemophilus parainfluenzae</i>	[23]
<i>Proteus mirabilis</i>	[34]
<i>Moraxella catarrhalis</i>	[6]

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin susceptible *Staphylococcus aureus*.

ADVANTAGES

As compared to other antibiotics used for clinical purposes, cephalosporins have low resistance and more activity against most pathogens. Its safety profile is similar to those currently available microbes to treat these infections. Some adverse effects of cephalosporins are also present such as vomiting, diarrhea, nausea but some serious effects anaphylaxis and respiratory failure also occur. The frequency of such antibiotics to develop resistant with major pathogens is low. Cephalosporins are used with more resistant and demonstrated with such pathogens and not used in the treatment of patients. These have activity also to treat bacterial isolates including various pathogens. Cephalosporin treat the most common pathogen with low propensity for drugs interactions and its good alternative agent for those who do not tolerate or respond to other antibacterial therapies [30].

DISADVANTAGES

Cephalosporin has been tested on specific population of patients and not useful for skin and skin structure infections because it has adverse effects. Its use because various infections to treat one type of infection causes other risk factors. Cephalosporins are used intravenously. Intramuscular administration has been studied but not approved. There is no oral preparation of this antibiotic. Different generations of cephalosporins have various doses and have various reports against them. Currently there are no cost benefits by use of cephalosporins in the treatment of patients but the current cost of this medication higher. Intravenous formulation to treat various diseases increases the cost of this antibiotic. Vancomycin should be less expensive and it is the first generation

cephalosporin [31]. Caution should be undertaken while using these antibiotics and it has same safety profile as other cephalosporins. Clinically cephalosporins used to treat complicated skin structure and skin infections with these pathogens. Studies on other bacterial species are lacking efficacy. Its uses limited to the population where it has shown clinical efficacy [32].

CLINICAL USES

Respiratory tract infections

Cephalosporins have advantage over other antibiotics or other generations of cephalosporins like ampicillin and amoxicillin in otitis media. Cephalosporin other generation antibiotics is more useful than other erythromycin antibiotics for penicillin allergic patients. Like cefaclor another cephalosporin more efficacious than other antibiotics likes erythromycin and sulphonamide to cure patients of otitis media of children which are developed. Amoxicillin more effective and must be 1st generation antibiotic. Oral or parenteral cephalosporin has no evidence to treat only chronic bronchitis [33]. It is possible that other antibiotics like cefotaxime or cefoperazone would be more beneficial in the 1st generation therapy of patients who have infectious by *Streptococcus pneumoniae* and *Hemophilus influenza* require hospital treatment [34].

All cephalosporins cure *Pneumococcal pneumonia* because it will be present outside the boundary of hospital but benzylpenicillin more effective used by intramuscular injection. When pneumonia caused by *Hemophilus pneumonia* then cephamandole used against that infection. Direct comparison of all that antibiotics discussed has not been reported. Cefuroxime

is more useful than antibacterially and pharmacologically to other antibiotics. Semi synthetic penicillin for staphylococcus species target but cephalosporins used and it should be older one than

other antibiotics. Cephalosporins are now used to aminoglycosides for the treatment of other diseases and other pneumonia agents treated by other cephalosporin generation antibiotics [35].




Fig 4: cephalosporin converts to inactive metabolites

Lungs or pulmonary infections mostly due to in hospital by organism like aeruginosa, *Enterobacter sp.*, *E. coli* or often in combination with other mouth flora. Mostly mouth flora anaerobes and *Enterobacter sp.* treated by cefoxitin agent and other antibiotics. Some penicillin also used more useful for the cure of diseases infectious by pathogens. Pulmonary diseases due to anaerobic flora have been treated by old and new cephalosporins and there have been no other antibiotics which have been more choiceful in such infections [36]. Bacterial pulmonary diseases in children and adults with cystic fibrosis cured by cephalosporin antibiotics and these diseases caused by aeruginosa species. Tetracycline also remains the choice of drug for other group of organisms.

Urinary tract infections

Oral cephalosporins are mostly useful for the cure of urinary tract infections in domicile and hospital settings. For the cure of lower tract infections single dose of some antibiotics is mostly useful and preferred. In hospital urinary tract infections due to multiple pathogens agents cause non pathogenic alternative to the aminoglycosides. 70% treatment rate with these new agents that have these activities in vitro. *Pseudomonas* such organism which are only cured by cephalosporins none other antibiotic that has more preferable activity against this organism. Upper urinary tract infection also treated by cephalosporins within 10-14 days [37].

Intra abdominal infections

Facultative bacilli and other anaerobic bacteria are caused by intestinal mucosa that results from

breaches in intra abdominal infections. Cephalosporins have chemotherapeutic role in such infections. Cefoxitin have proved as effective as amino glycosides. If *pseudomonas* like other organism present and infectious caused by in case of hospital cure or after use of these antibiotics, cephalosporins antibiotics used until culture results known. Single therapy is more effective than combined antibiotics equal to or more effectively used. The doses of some antibiotics were lower than favored by most physicians [38]. So, third generation cephalosporin is more effective for the treatment of intra abdominal infections mostly when there is concerned with renal toxicity. Some antibiotics most actively used agent and should be main component of infections.

Gastrointestinal infections

Salmonella and *shigella* species disapproved the oral and parenteral cephalosporins. Cefotaxime more effective with *salmonella* infections but other antibiotics used as next base choice for the treatment of this disease. Some bacterial species have no effects and no reports of infections occurred by this organism. Any of all those of cephalosporins can be used to cure diarrhea. Some membranous infections have occurred with many of cephalosporins [39].

Hepatobiliary infections

Enterobacter species, *E. coli* caused infection in biliary tract. Anaerobes are most useful when there has been operate or in special case diabetes in who spore forming bacteria may be the pathogen. Cephalosporin antibiotics all proved useful in such

infections. When there has been infection due to these bacteria agents such as preferred agent would be piperacillin. Liver diseases are due to anaerobic species in which aforementioned penicillins may give better results [40].

Gynaecological infections

Cephalosporin antibiotics have no role in treatment of inflammatory disease. Oral cephalosporin also used in such infections. Bacteria cause infections in the patient who treated by radiation therapy or cytotoxic. *E. coli* and other bacteria are the important pathogens. Cephalosporin has proved excellent therapy. Third generation cephalosporins and cefoxitin should be gynecological infections and prevent formation and surgical invention [41].

Sexually transmitted diseases

Penicillinase producing bacteria provide an important area for cephalosporin antibiotics. The best agent maybe antibiotic and have 8 hours serum half life and have dose as low as 250 mg in intramuscular injection. It also resulted more reacted against man as well as rabbit and it will be important for the treatment of sexually transmitted diseases. One drawback of these new agents is their deficiency of inhibitory activity against some species [42].

Skin and soft tissue infections

Streptococcus species and other bacterial species cause skin and soft tissue infections are best treated by benzyl penicillin and other antibiotics. Cephalosporin with penicillin is therapeutic agent possibility in adults and erythromycin in children. Infections by bites or closed injuries are when responsible organism bacteria treated with penicillin. Gram negative bacilli and anaerobic bacteria cause ulcers and peripheral vascular diseases are associated with cephalosporins. Third generation cephalosporin is most useful and active related to all these infections. But most other agents are associated when *Pseudomonas* has been present [43, 44].

Bone and joint infections

Bacterial species are treated by earlier cephalosporins and have resulted best treatment against these antibiotics. In the patient with penicillin allergy with penicillinase producing bacteria now give cured by antibiotics. The total number of patients which have this

disease tested with new cephalosporin has been small. All cephalosporin antibiotics are effective and no one regarded as first choice. The efficacy of new cephalosporins is not well established. While other generations of cephalosporins was undecided. These agents now used for the treatment of these diseases [45].

Cardiovascular infections

Penicillin alternative is first generation cephalosporin have been used due to bacterial species remain the first choice. Gram negative on the left side of heart is a disease cured by surgery and has cured with any of the new agents [46].

Central nervous system infections

First and second generation cephalosporin have been used for the therapy of central infections. Chemotherapy results are available of new cephalosporin and some antibiotics are used as first initial therapy of this infection which caused by some bacterial species. In some countries *Listeria* and other species are also important. Mortality rate was also reduced by these cephalosporins. None of these agents is satisfactory and superior to these kinds of bacteria. Cefotaxime has proved to be excellent therapy of such infections and single agent can not be used or effective in other species. Cephalosporins old and new have no role but it have minor role in the therapy of brain and other bacterial species are the important pathogens [47-50].

FUTURE INVESTIGATIONS

The studies of antimicrobial resistance remain concern for the development of novel agents. Future studies on drugs clinical impact on pneumonia should be explored in species and other infections caused by pathogens. The use of cephalosporin against pneumonia explored in other populations such patients in ICU or with septic shock or any other infecting organ and requiring renal replacement therapy. Cephalosporins wide coverage of gram positive and gram negative pathogens in combining this antibiotic with other pathogens to provide additional pathogen coverage. Preliminary models are promising. The clinical implications of this drug combination are encouraging in an era of increasing multi-resistant pathogen induced infections.

Table-2: Indications for cephalosporin

Diseases	Antibiotics	References
Respiratory tract infections Otitis media <i>Streptococcus pneumonia</i> <i>Hemophilus influenza</i> <i>Staphylococcus aureus</i> Klebsiella Pseudomonas Anaerobic organisms	Cefaclor 1 st generation agent Cefotaxime Cefazolin Cefotaxime Ceftazidime Cefoxitin	[15]
Urinary tract infections Enterobacteriaceae Pseudomonas	Cefotaxime Ceftazidime	[35]
Central nervous system infections Neonatal <i>Streptococcus pneumonia</i> <i>Hemophilus influenza</i> Enterobacteriaceae	Cefotaxime Cefotaxime Cefotaxime Cefotaxime	[43]
Bone and joint infections <i>Staphylococcus aureus</i> Enterobacteriaceae Pseudomonas	Cefazolin Cefotaxime Ceftazidime	[22]
Diarrhoeal diseases Shigella Salmonella Campylobacter	None	[10]
Sexually transmitted diseases Gonorrhoea	Cefoxitin	[28]

CONCLUSION

Cephalosporin, a fifth generation antibiotic used for the treatment of community acquired patients in hospitalized patients. But its high potency also caused various effects on human body and does not effect the bacterial infections. Even this antibiotic FDA approved but its high dosage also cause various side effects. Recent studies on cephalosporin to improve its efficiency and resistant to more pathogens when it used with other antibiotic it is more resistant and also resist gram negative bacteria. In appropriate use of cephalosporin cause various resistant strains to enter in hospital environment or community like various bacterial pathogens. In a time of enhancing resistant drug infections, provide the additional treatment of already antibiotics.

REFERENCES

1. Arcuri EJ, Nicholas J, Brix T, Santamarina V, Drew S. Molecular characterization of antibiotics. *Biotechnol Bioengin* 2005; 25:2399.
2. Aspa J, Rajas O, Rodríguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, España PP, Rello J. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. *Clinical Infectious Diseases*. 2004 Mar 15; 38(6):787-98.
3. Bhat SV, Nagasmpagi BA, Sivakumar M. 2005. Chemistry of natural product. *Clin Infect Dis* 2005; 38(6):787-98.
4. Guiseley KB. Chemical and physical properties of algal polysaccharides used for cell immobilization. *Enzyme and Microbial Technology*. 1989 Nov 1; 11(11):706-16.
5. Hasan F, Khan S, Shah AA, Hameed A. Production of antibacterial compounds by free and immobilized *Bacillus pumilus* SAF1. *Pak. J. Bot.* 2009 Jun 1; 41(3):1499-510.
6. Higgins CE, Hamill RL, Sands TH, Hoehn MM, Davis NE, Nagarajan R, Boeck LD. The Occurrence Of Deacetoxy-Cephalosporin C In Fungi And Streptomycetes. *The Journal of antibiotics*. 1974; 27(4):298-300.
7. Hota B, Lyles R, Rim J, Popovich KJ, Rice T, Aroutcheva A, Weinstein RA. Predictors of clinical virulence in community-onset methicillin-resistant *Staphylococcus aureus* infections: the importance of USA300 and pneumonia. *Clinical Infectious Diseases*. 2011 Oct 15; 53(8):757-65.
8. Johansen A, Flink JM. Influence of alginate properties and gel reinforcement on fermentation characteristics of immobilized yeast cells. *Enzyme and microbial technology*. 1986 Dec 1; 8(12):737-48.

9. Kim JC, Kang SW, Lim JS, Song YS, Kim SW. Stimulation of cephalosporin C production by *Acremonium chrysogenum* M35 with fatty acids. *Journal of Microbiology and Biotechnology*. 2006 Jul 1; 16(7):1120-4.
10. Schmitt Y, Karube I, Suzuki S. Regulation of cephalosporin biosynthesis. *J Biochem Tech* 2004; 88:1-43.
11. Silva AS, Cruz AJ, Araujo ML, Hokka CO. The effect of the addition of invert sugar on the production of cephalosporin C in a fed-batch bioreactor. *Brazilian Journal of Chemical Engineering*. 1998 Dec; 15(4):320-5.
12. Stryjewski ME, Corey G. New treatments for methicillin-resistant *Staphylococcus aureus*. *Curr Opin Crit Care* 2013; 15(5):403-12.
13. Boucher HW, Corey GR. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clinical infectious diseases*. 2008 Jun 1; 46(Supplement 5):S344-9.
14. Brakhage AA. Molecular regulation of β -lactam biosynthesis in filamentous fungi. *Microbiology and Molecular Biology Reviews*. 1998 Sep 1; 62(3):547-85.
15. Campos Muniz C, Tania ECZ, Gabriela Rodriguez E, Francisco Fernandez J. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2007; 46: 344-49.
16. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β -lactams for penicillin-binding proteins from *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Antimicrobial agents and chemotherapy*. 2010 May 1; 54(5):1670-7.
17. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: a meta-analysis. *Clinical infectious diseases*. 2003 Jan 1; 36(1):53-9.
18. Cruz AJ, Pan T, Giordano RC, Araujo ML, Hokka CO. Cephalosporin C production by immobilized *Cephalosporium acremonium* cells in a repeated batch tower bioreactor. *Biotechnology and bioengineering*. 2004 Jan 5; 85(1):96-102.
19. Cuadra T, Fernandez FJ, Tomasini A, Barrios-González J. Influence of pH regulation and nutrient content on cephalosporin C production in solid-state fermentation by *Acremonium chrysogenum* C10. *Letters in applied microbiology*. 2008 Feb 1; 46(2):216-20.
20. Dasari VR, Donthireddy SR, Nikku MY, Garapati HR. Optimization of medium constituents for Cephalosporin C production using response surface methodology and artificial neural networks. *Journal of biochemical technology*. 2009 Feb 25; 1(3):69-74.
21. David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic. *Clinical microbiology reviews*. 2010 Jul 1; 23(3):616-87.
22. Demain AL, Zhang J. Cephalosporin C production by *Cephalosporium acremonium*: the methionine story. *Critical reviews in biotechnology*. 1998 Jan 1; 18(4):283-94.
23. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, Beekmann S. Antimicrobial resistance among *Streptococcus pneumoniae* in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? *Clinical infectious diseases*. 2005 Jul 15; 41(2):139-48.
24. Elander RP. Industrial production of β -lactam antibiotics. *Applied microbiology and biotechnology*. 2003 Jun 1; 61(5-6):385-92.
25. Falcó V, Almirante B, Jordano Q, Calonge L, Del Valle O, Pigrau C, Planes AM, Gavaldà J, Pahissa A. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?. *Journal of Antimicrobial Chemotherapy*. 2004 Aug 1; 54(2):481-8.
26. Ferrer M, Menendez R, Amaro R, Torres A. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. *Clinics in chest medicine*. 2011 Sep 30; 32(3):491-505.
27. Foster BC, Coutts R, Pasutto F, Dossetor J. Production of antibiotics. *Biotechnol Lett* 2013; 5:693.
28. Kim JC, Song YS, Lee DH, Kang SW, Kim SW. Fatty acids reduce the tensile strength of fungal hyphae during cephalosporin C production in *Acremonium chrysogenum*. *Biotechnology letters*. 2007 Jan 1; 29(1):51-5.
29. Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among *Streptococcus pneumoniae*: implications for therapy. In *Seminars in respiratory and critical care medicine* 2005 Dec (Vol. 26, No. 06, pp. 575-616). Copyright© 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
30. Lynch JP, Zhanel GG. *Streptococcus pneumoniae*: does antimicrobial resistance matter? In *Seminars in respiratory and critical care medicine* 2009 Apr (Vol. 30, No. 02, pp. 210-238). © Thieme Medical Publishers.
31. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

- Clinical infectious diseases. 2007 Mar 1; 44(Supplement 2):S27-72.
32. Masuda G, Tomioka S. Quantitative assessment of bactericidal activities of β -lactam antibiotics by agar plate method. *Antimicrobial agents and chemotherapy*. 1978 Oct 1; 14(4):587-95.
 33. Mays DL, Bangert FK, Cantrell WC, Evans WG. Hydroxylamine determination of cephalosporin. *Anal Chem* 1975; 47:2229-34.
 34. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. *Archives of Internal Medicine*. 2009 Sep 12; 169(16):1525-31.
 35. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. *Clinical infectious diseases*. 2000 Mar 1; 30(3):520-8.
 36. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β -lactams for penicillin-binding proteins from *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Antimicrobial agents and chemotherapy*. 2010 May 1; 54(5):1670-7.
 37. Villegas-Estrada A, Lee M, Heseck D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant *Staphylococcus aureus*: potent inhibition of PBP 2a by two anti-MRSA β -lactam antibiotics. *Journal of the American Chemical Society*. 2008 Jun 27; 130(29):9212-3.
 38. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant *Staphylococcus aureus* bacteraemia: a meta-analysis. *Medical Journal of Australia*. 2001 Sep 3; 175(5):264-7.
 39. Wittler R, Schugerl K. Agar used as immobilization of fungal strain for production of cephalosporin. *Appl Microbiol Biotechnol* 2010; 21:348-55.
 40. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Höök M, Etienne J, Vandenesch F. *Staphylococcus aureus* Panton-Valentine leukocidin causes necrotizing pneumonia. *Science*. 2007 Feb 23; 315(5815):1130-3.
 41. Morikawa Y, Karube I, Suzuki S. Productin of cephalosporin by immobilization. *Biotechnol Bioengin* 2012; 2:15.
 42. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martín R, Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. *New England Journal of Medicine*. 1995 Aug 24; 333(8):474-80.
 43. David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic. *Clinical microbiology reviews*. 2010 Jul 1; 23(3):616-87.
 44. Rosenthal VD, Maki D, Jamulitrat S. International nosocomial infection control consortium (INICC) report, data summary for 2003–2008 issued Jun 2009. *Am J Infect Control* 2010; 38(2):95-04.
 45. Taneja C, Haque N, Oster G. Clinical and economic outcomes in patients with community-acquired *Staphylococcus aureus* pneumonia. *J Hosp Med* 2010; 5(9):528-34.
 46. Tenover FC, Goering RV. Methicillin-resistant *Staphylococcus aureus* strain USA300: origin and epidemiology. *Journal of Antimicrobial Chemotherapy*. 2009 Sep 1; 64(3):441-6.
 47. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. *Clinical infectious diseases*. 2006 Mar 15; 42(6):788-97.
 48. Tollnick C, Seidel G, Beyer M, Schügerl K. Investigations of the production of cephalosporin C by *Acremonium chrysogenum*. *New Trends and Developments in Biochemical Engineering*. 2004:1-21.
 49. Trilli A, Michelini V, Mantovani V, Pirt SJ. Development of the agar disk method for the rapid selection of cephalosporin producers with improved yields. *Antimicrobial agents and chemotherapy*. 1978 Jan 1; 13(1):7-13.
 50. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. *Clinical infectious diseases*. 1999 Jul 15; 29(2):321-7.